Difference between revisions of "Part:BBa K1230004"
| (6 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K1230004 short</partinfo> | <partinfo>BBa_K1230004 short</partinfo> | ||
| Line 7: | Line 6: | ||
This composite part allows MarA expression in presence of IPTG, by using the LacI promoter and the RBS based on Elowitz repressilator (Part BBa_J04500) | This composite part allows MarA expression in presence of IPTG, by using the LacI promoter and the RBS based on Elowitz repressilator (Part BBa_J04500) | ||
| + | <b>Characterization</b> | ||
| + | |||
| + | We were able to characterise this part, since we found a measurable phenotype (kanamycin resistance). | ||
| + | |||
| + | |||
| + | We also characterised it using Kanamycin �Minimum Inhibitory Concentration� (MIC) finding a MIC with MarA overexpression: 5 µg/ml and a wild-type MIC: 1 µg/ml | ||
| + | |||
| + | |||
| + | |||
| + | https://static.igem.org/mediawiki/igem.org/8/8b/U102_Fig2.png | ||
| + | |||
| + | A test was performed with three different antibiotics and different IPTG concentrations. | ||
| + | The part seems to make the host sensible to Tetracyclin (maybe because it's on Cm plasmid, and both antibiotics act on similar ways), it seems not to have an effect on Ampicilin and it shows a relevant effect with Kanamycin. Which is further explored in the next figure. | ||
| + | |||
| + | https://static.igem.org/mediawiki/igem.org/2/21/U101_Fig3.png | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
===Usage and Biology=== | ===Usage and Biology=== | ||
| Line 18: | Line 32: | ||
===Functional Parameters=== | ===Functional Parameters=== | ||
<partinfo>BBa_K1230004 parameters</partinfo> | <partinfo>BBa_K1230004 parameters</partinfo> | ||
| + | |||
<!-- --> | <!-- --> | ||
Latest revision as of 22:07, 5 October 2013
MarA Generator
The MarA protein acts as a transcriptional activator in E. coli. It allows the expression of the acrAB and tolC operons, which activate the AcrAB-TolC efflux pump, a mechanism that has been related with resistance to organic solvents, dyes, detergents, antibiotics such as chloramphenicol, tetracycline, novobiocin, erythromycin, fusidic acid and cloxacillin, as well as to cationic antimicrobial peptides, such as LL-37, HNP-2 and HBD-1.
This composite part allows MarA expression in presence of IPTG, by using the LacI promoter and the RBS based on Elowitz repressilator (Part BBa_J04500)
Characterization
We were able to characterise this part, since we found a measurable phenotype (kanamycin resistance).
We also characterised it using Kanamycin �Minimum Inhibitory Concentration� (MIC) finding a MIC with MarA overexpression: 5 µg/ml and a wild-type MIC: 1 µg/ml
A test was performed with three different antibiotics and different IPTG concentrations. The part seems to make the host sensible to Tetracyclin (maybe because it's on Cm plasmid, and both antibiotics act on similar ways), it seems not to have an effect on Ampicilin and it shows a relevant effect with Kanamycin. Which is further explored in the next figure.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal AgeI site found at 380
- 1000COMPATIBLE WITH RFC[1000]